Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136683 | 0.73 | — | — | |
| SCHEMBL19659142 | 0.72 | — | — | |
| SCHEMBL9190792 | 0.71 | — | — | |
| SCHEMBL35212276 | 0.71 | — | — | |
| SCHEMBL15181868 | 0.69 | — | — | |
| SCHEMBL31485576 | 0.69 | TRIM24 (0.30) | TRIM24TRIM33 | |
| SCHEMBL9171769 | 0.65 | TRIM24 (0.44) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL31071613 | 0.65 | — | — | |
| SCHEMBL30876775 | 0.65 | TRIM24 (0.45) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL9902103 | 0.63 | MEN1 (0.32) | MEN1CYP2C9KMT2ATRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250205244-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E THERAPEUTICS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250186436-A1 | SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | 4E THERAPEUTICS, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4464703-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4245756-B1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-3886845-B1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4380566-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020112581-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2013185202-A1 | APOPTOSIS INDUCERS | BETA PHARMA CANADA INC (CA) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013185202-A1 | APOPTOSIS INDUCERS | BETA PHARMA CANADA INC (CA) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186436-A1 | SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NIM1K, NEK1, NEK11 | MEN1 787/4885CYP2C9 1764/4885KMT2A 2555/4885 |
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | IKZF2, IKZF1, IKZF3 | MEN1 2725/4885CYP2C9 4073/4885KMT2A 318/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | MEN1 128/4885CYP2C9 34/4885KMT2A 3390/4885 |
| US-20250205244-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | DMPK, NIM1K, CAMKK2 | MEN1 187/4885CYP2C9 3308/4885KMT2A 358/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | MEN1 128/4885CYP2C9 34/4885KMT2A 3390/4885 |
| US-12264134-B2 | Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, AADAC | MEN1 3496/4885CYP2C9 2042/4885KMT2A 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.